KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $1.3 million.

  • Neogenomics' Cash from Operations fell 8629.59% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 million, marking a year-over-year decrease of 2553.04%. This contributed to the annual value of $5.2 million for FY2025, which is 2553.04% down from last year.
  • Latest data reveals that Neogenomics reported Cash from Operations of $1.3 million as of Q4 2025, which was down 8629.59% from $8.9 million recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' Cash from Operations peaked at $20.3 million during Q2 2025, and registered a low of -$29.0 million during Q1 2022.
  • In the last 5 years, Neogenomics' Cash from Operations had a median value of -$2.6 million in 2022 and averaged -$4.1 million.
  • As far as peak fluctuations go, Neogenomics' Cash from Operations plummeted by 157661.6% in 2021, and later soared by 99741.6% in 2024.
  • Quarter analysis of 5 years shows Neogenomics' Cash from Operations stood at -$19.8 million in 2021, then skyrocketed by 81.37% to -$3.7 million in 2022, then surged by 582.61% to $17.8 million in 2023, then tumbled by 44.89% to $9.8 million in 2024, then tumbled by 86.3% to $1.3 million in 2025.
  • Its Cash from Operations stands at $1.3 million for Q4 2025, versus $8.9 million for Q3 2025 and $20.3 million for Q2 2025.